PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels. / Kim, Robin Y; Pless, Stephan A; Kurata, Harley T.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, No. 45, 23.10.2017, p. E9702–E9711.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kim, RY, Pless, SA & Kurata, HT 2017, 'PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels', Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 45, pp. E9702–E9711. https://doi.org/10.1073/pnas.1705802114

APA

Kim, R. Y., Pless, S. A., & Kurata, H. T. (2017). PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels. Proceedings of the National Academy of Sciences of the United States of America, 114(45), E9702–E9711. https://doi.org/10.1073/pnas.1705802114

Vancouver

Kim RY, Pless SA, Kurata HT. PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels. Proceedings of the National Academy of Sciences of the United States of America. 2017 Oct 23;114(45):E9702–E9711. https://doi.org/10.1073/pnas.1705802114

Author

Kim, Robin Y ; Pless, Stephan A ; Kurata, Harley T. / PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels. In: Proceedings of the National Academy of Sciences of the United States of America. 2017 ; Vol. 114, No. 45. pp. E9702–E9711.

Bibtex

@article{528f8d461ed54f2692413ad1190d0a27,
title = "PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels",
abstract = "Retigabine (RTG) is a first-in-class antiepileptic drug that suppresses neuronal excitability through the activation of voltage-gated KCNQ2-5 potassium channels. Retigabine binds to the pore-forming domain, causing a hyperpolarizing shift in the voltage dependence of channel activation. To elucidate how the retigabine binding site is coupled to changes in voltage sensing, we used voltage-clamp fluorometry to track conformational changes of the KCNQ3 voltage-sensing domains (VSDs) in response to voltage, retigabine, and PIP2. Steady-state ionic conductance and voltage sensor fluorescence closely overlap under basal PIP2 conditions. Retigabine stabilizes the conducting conformation of the pore and the activated voltage sensor conformation, leading to dramatic deceleration of current and fluorescence deactivation, but these effects are attenuated upon disruption of channel:PIP2 interactions. These findings reveal an important role for PIP2 in coupling retigabine binding to altered VSD function. We identify a polybasic motif in the proximal C terminus of retigabine-sensitive KCNQ channels that contributes to VSD-pore coupling via PIP2, and thereby influences the unique gating effects of retigabine.",
keywords = "Journal Article",
author = "Kim, {Robin Y} and Pless, {Stephan A} and Kurata, {Harley T}",
note = "Copyright {\textcopyright} 2017 the Author(s). Published by PNAS.",
year = "2017",
month = oct,
day = "23",
doi = "10.1073/pnas.1705802114",
language = "English",
volume = "114",
pages = "E9702–E9711",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "The National Academy of Sciences of the United States of America",
number = "45",

}

RIS

TY - JOUR

T1 - PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels

AU - Kim, Robin Y

AU - Pless, Stephan A

AU - Kurata, Harley T

N1 - Copyright © 2017 the Author(s). Published by PNAS.

PY - 2017/10/23

Y1 - 2017/10/23

N2 - Retigabine (RTG) is a first-in-class antiepileptic drug that suppresses neuronal excitability through the activation of voltage-gated KCNQ2-5 potassium channels. Retigabine binds to the pore-forming domain, causing a hyperpolarizing shift in the voltage dependence of channel activation. To elucidate how the retigabine binding site is coupled to changes in voltage sensing, we used voltage-clamp fluorometry to track conformational changes of the KCNQ3 voltage-sensing domains (VSDs) in response to voltage, retigabine, and PIP2. Steady-state ionic conductance and voltage sensor fluorescence closely overlap under basal PIP2 conditions. Retigabine stabilizes the conducting conformation of the pore and the activated voltage sensor conformation, leading to dramatic deceleration of current and fluorescence deactivation, but these effects are attenuated upon disruption of channel:PIP2 interactions. These findings reveal an important role for PIP2 in coupling retigabine binding to altered VSD function. We identify a polybasic motif in the proximal C terminus of retigabine-sensitive KCNQ channels that contributes to VSD-pore coupling via PIP2, and thereby influences the unique gating effects of retigabine.

AB - Retigabine (RTG) is a first-in-class antiepileptic drug that suppresses neuronal excitability through the activation of voltage-gated KCNQ2-5 potassium channels. Retigabine binds to the pore-forming domain, causing a hyperpolarizing shift in the voltage dependence of channel activation. To elucidate how the retigabine binding site is coupled to changes in voltage sensing, we used voltage-clamp fluorometry to track conformational changes of the KCNQ3 voltage-sensing domains (VSDs) in response to voltage, retigabine, and PIP2. Steady-state ionic conductance and voltage sensor fluorescence closely overlap under basal PIP2 conditions. Retigabine stabilizes the conducting conformation of the pore and the activated voltage sensor conformation, leading to dramatic deceleration of current and fluorescence deactivation, but these effects are attenuated upon disruption of channel:PIP2 interactions. These findings reveal an important role for PIP2 in coupling retigabine binding to altered VSD function. We identify a polybasic motif in the proximal C terminus of retigabine-sensitive KCNQ channels that contributes to VSD-pore coupling via PIP2, and thereby influences the unique gating effects of retigabine.

KW - Journal Article

U2 - 10.1073/pnas.1705802114

DO - 10.1073/pnas.1705802114

M3 - Journal article

C2 - 29078287

VL - 114

SP - E9702–E9711

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 45

ER -

ID: 185012087